# Odyssey Therapeutics Shares Design for Phase 2a Ulcerative Colitis Trial

- URL: https://stocks.freetheai.org/news/odyssey-therapeutics-shares-design-for-phase-2a-ulcerative-colitis-trial-783cdc
- Published: 2026-10-12T12:00:00Z
- Category: company_news; sentiment: bullish; impact: medium
- Symbols: [NASDAQ:ODTX](https://stocks.freetheai.org/symbols/NASDAQ-ODTX)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Odyssey Therapeutics, Inc. (ODTX) is presenting the design for a Phase 2a clinical study of its drug candidate OD-001 at the American College of Gastroenterology 2026 Annual Scientific Meeting. The randomized, double-blind trial will evaluate OD-001 in combination with vedolizumab for patients diagnosed with moderate-to-severe ulcerative colitis.

The trial aims to test a dual approach to treating gut inflammation by combining two different mechanisms. OD-001 acts as a RIPK2 scaffolding inhibitor targeting innate immune activation, while vedolizumab restricts adaptive immune cell movement to the digestive tract. The study will enroll up to 146 patients globally to evaluate the combination over a 12-week induction phase, followed by 52 weeks of OD-001 monotherapy maintenance.

Investors and healthcare professionals can expect topline induction results from the clinical trial in the second half of 2027. Shares of Odyssey Therapeutics traded at $19, up 4.86% following the announcement.

## Key points

- Odyssey Therapeutics, Inc. (ODTX) is presenting the trial design for its Phase 2a ulcerative colitis study at the ACG 2026 Annual Scientific Meeting.
- The trial tests OD-001 in combination with vedolizumab across up to 146 global patients with moderate-to-severe ulcerative colitis.
- The treatment strategy targets both innate and adaptive immune systems to address intestinal inflammation.
- Topline results for the trial's 12-week induction period are expected in the second half of 2027.

## Questions and answers

### What is Odyssey Therapeutics presenting at ACG 2026?

Odyssey Therapeutics is presenting the study design for its Phase 2a clinical trial evaluating OD-001 combined with vedolizumab in patients with moderate-to-severe ulcerative colitis.

### How many patients will participate in the OD-001 Phase 2a trial?

The clinical trial is expected to enroll up to 146 patients globally.

### When will trial results for OD-001 be available?

Odyssey Therapeutics expects to release topline induction results from the trial in the second half of 2027.